At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Nov 12, 2026 at 16:01 ET
Curis reported Q3 2026 net loss of $8.1M ($1.94 per share) with zero revenue after selling Erivedge royalties in Q4 2025. The company has $5.0M cash plus $7.5M from an October private placement, funding operations only into Q1 2027, and faces Nasdaq delisting risk. Clinical progress in emavusertib studies is early-stage with no near-term revenue catalyst.
- Q3 2026 net loss $8.1M ($1.94 per share) vs $7.7M ($9.86) in Q3 2025
- Zero revenue in Q3 2026 after Erivedge royalty sale in Q4 2025
- Cash and equivalents $5.0M as of Sep 30, 2026; plus $7.5M from Oct 2026 private placement
- Cash runway only into Q1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access